[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100536880":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":29,"centralContacts":29,"locations":30,"responsibleParty":53,"collaborators":29,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":64,"sex":65,"minAge":66,"maxAge":29,"enrollmentInfo":67,"targetDuration":29,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":29,"overallStatus":77,"whyStopped":29,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"National Jewish Health","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Asthma Group","ACTIVE_COMPARATOR","Subjects diagnosed with one of the three asthma endotypes being studied (T2, T1, or T17).",[13],"Drug: Lipopolysaccharides",{"label":15,"type":10,"description":16,"interventionNames":17},"Control Group","Subjects with no diagnosis of asthma or other respiratory disease and are deemed healthy.",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","Lipopolysaccharides","LPS aka endotoxin is a component of bacterial cell walls and is ubiquitous in the environment. It is found in pet dander, house dust and environmental dusts and has been heavily studied in asthma.",[9,15],[25,26,27,28],"Endotoxin","LPS","Clinical reference center lipopolysaccharide","LPS E. Coli O:113",null,[31],{"facility":5,"status":29,"city":32,"state":33,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"Denver","Colorado","80206","United States","US",{"type":38,"coordinates":39},"Point",[40,41],-104.9847,39.73915,{"lat":41,"lon":40},[44,48,51],{"name":45,"role":46,"phone":47,"phoneExt":29,"email":29},"William J Janssen, MD","CONTACT","303-398-1366",{"name":49,"role":46,"phone":50,"phoneExt":29,"email":29},"Olivia M VerBurg, BA","303-398-1201",{"name":45,"role":52,"phone":29,"phoneExt":29,"email":29},"PRINCIPAL_INVESTIGATOR",{"type":52,"investigatorFullName":54,"investigatorTitle":55,"investigatorAffiliation":5,"oldNameTitle":29,"oldOrganization":29},"William Janssen, MD","Section Head of Critical Care, Professor of Medicine, Principle Investigator","100536880","phase-1-nasal-inflammation-following-endotoxin-challenge-in-patients-with-asthma-100536880",false,"NCT06270576","Nasal Inflammation Following Endotoxin Challenge in Patients With Asthma","Nasal Endotoxin Challenge to Study Mucosal Inflammation in Patients With Asthma","Nasal-LPS","Inclusion Criteria:\n\n* Participants will have asthma diagnosed by a health care provider. Healthy controls are individuals without asthma.\n* Written informed consent\n\nExclusion Criteria:\n\n* Current or recent illness (in the past 4 weeks)\n* Recent asthma exacerbation (past 4 weeks)\n* History of nasal perforation or nasal surgery\n* Nasal polyposis\n* Presence or prior history of cardiac or systemic disease\n* Bleeding disorder, use of systemic anticoagulants, or antiplatelet therapy\n* Immunocompromised state (HIV, immunoglobulin deficiency, systemic immunosuppressants excluding corticosteroids)\n* Use of tobacco or marijuana in the past 2 months or greater than a 10 pack-year smoking history\n* Currently pregnant or breastfeeding",true,"ALL","18 Years",{"count":68,"type":69},60,"ESTIMATED","INTERVENTIONAL",[72],"PHASE1","A phase I clinical research study aimed at determining mechanisms that regulate airway mucosal inflammation in asthma endotypes using intranasal administration of endotoxin (lipopolysaccharide from E. coli) in healthy controls and subjects diagnosed with asthma.",[75,76],"Asthma; Eosinophilic","Asthma","NOT_YET_RECRUITING","2024-02-13",{"date":80,"type":81},"2024-02-21","ACTUAL",{"date":83,"type":69},"2024-04",{"date":85,"type":69},"2028-06",{"name":5,"class":6},1]